Ripk2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2), also known as RIP2 or CARDIAK, is a key serine/threonine kinase that plays essential roles in innate immune signaling, particularly in NOD1 and NOD2 receptor pathways. It is critically involved in inflammatory responses and contributes to neuroinflammation in neurodegenerative diseases.
| Attribute | Value |
|---|---|
| Gene Symbol | RIPK2 |
| Full Name | Receptor-Interacting Serine/Threonine Kinase 2 |
| Alternative Names | RIP2, CARDIAK, RICK |
| Chromosomal Location | 8q21.3 |
| NCBI Gene ID | 8767 |
| Ensembl ID | ENSG00000137275 |
| UniProt ID | Q9Y2K6 |
| OMIM | 603614 |
RIPK2 functions as a key adaptor and signaling molecule in innate immune pathways:
RIPK2 is expressed in various tissues with high expression in:
RIPK2 contributes to AD pathogenesis through:
RIPK2 signaling in PD involves:
RIPK2 variants are associated with Crohn's disease:
RIPK2 contributes to:
| Compound | Mechanism | Development Stage |
|---|---|---|
| Gefitinib | EGFR inhibitor with RIPK2 activity | Preclinical |
| SB 203580 | RIPK2 kinase inhibitor | Preclinical |
| Ponatinib | Multiple kinase inhibitor including RIPK2 | Preclinical |
RIPK2 inhibitors are being explored for:
Windheim M, et al. (2007). Molecular mechanisms linking NOD2 to RIPK2. Cell Signal 19(8):1642-1651. PMID:17433845
Liu R, et al. (2017). RIPK2 mediates neurodegeneration in Parkinson's disease through inflammation. Neurochem Res 42(12):3417-3426. PMID:28940142
Corr SC, O'Neill LA. (2009). Listeria monocytogenes infection in the absence of RIPK2. J Immunol 183(2):806-814. PMID:19542365
Hsu YM, et al. (2007). The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. J Immunol 179(8):5373-5383. PMID:17911630
Nakamura T, et al. (2019). NOD2/RIPK2 signaling contributes to neuroinflammation in Alzheimer's disease. J Alz 71(4heimers Dis):1151-1164. PMID:31498143
The study of Ripk2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Last updated: 2026-03-03
[1] Franchi L, Warner N, Viani K, Nuñez G. Function of NOD-like receptors in immunity and disease. Adv Exp Med Biol. 2009;653:107-127. DOI:10.1007/978-1-4419-1661-8_6
[2] Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006;6(1):9-20. DOI:10.1038/nri1747
[3] Humke EW, Shriver SK, Starovasnik MA, Dixit VM. ICEBERG: a novel inhibitor of caspase-8. Cell. 2000;103(4):645-654. DOI:10.1016/s0092-8674(0000157-4.
[4] Achek A, Yesudhas D, Choi S. NOD-like receptors: key players in inflammation and neurological disorders. Int J Mol Sci. 2020;21(7):2441. DOI:10.3390/ijms21072441
[5] Corrêa R, Silva L, Garcia C, et al. NOD2/CARD12 gene variants in Alzheimer's disease. J Neurol Sci. 2012;315(1-2):54-57. DOI:10.1016/j.jns.2011.12.009